메뉴 건너뛰기




Volumn 14, Issue 6, 2005, Pages 636-642

When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature

Author keywords

Adjuvant chemotherapy; Breast cancer; Cost effectiveness; Endocrine therapy; Health economics; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

EID: 28044461469     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.08.014     Document Type: Article
Times cited : (6)

References (21)
  • 1
    • 1642273148 scopus 로고    scopus 로고
    • Breast cancer from a public health perspective
    • R.R. Love S.M. Love A.V. Laudico Breast cancer from a public health perspective Breast J 10 2004 136-140
    • (2004) Breast J. , vol.10 , pp. 136-140
    • Love, R.R.1    Love, S.M.2    Laudico, A.V.3
  • 2
    • 15844425226 scopus 로고    scopus 로고
    • Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta analysis of quality-adjusted survival
    • R.D. Gelber B.F. Cole A. Goldhirsch C. Rose B. Fisher C.K. Osborne et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta analysis of quality-adjusted survival Lancet 347 1996 1057-1058
    • (1996) Lancet , vol.347 , pp. 1057-1058
    • Gelber, R.D.1    Cole, B.F.2    Goldhirsch, A.3    Rose, C.4    Fisher, B.5    Osborne, C.K.6
  • 3
    • 0037240367 scopus 로고    scopus 로고
    • Adjuvant hormonal therapy for premenopausal women with breast cancer
    • L.A. Emens N.E. Davidson Adjuvant hormonal therapy for premenopausal women with breast cancer Clin Cancer Res 9 Suppl. 2003 468s-494s
    • (2003) Clin. Cancer Res. , vol.9 , Issue.SUPPL.
    • Emens, L.A.1    Davidson, N.E.2
  • 4
    • 13244268450 scopus 로고    scopus 로고
    • 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study
    • G. Bonadonna A. Moliterni M. Zambetti M.G. Daidone S. Pilotti L. Gianni et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study BMJ 330 2005 217
    • (2005) BMJ , vol.330 , pp. 217
    • Bonadonna, G.1    Moliterni, A.2    Zambetti, M.3    Daidone, M.G.4    Pilotti, S.5    Gianni, L.6
  • 5
    • 0842308445 scopus 로고    scopus 로고
    • First-line endocrine treatment of breast cancer: Aromatase inhibitor or antiestrogen
    • Z.W. Wong M.J. Ellis First-line endocrine treatment of breast cancer: aromatase inhibitor or antiestrogen Br J Cancer 90 2004 20-25
    • (2004) Br. J. Cancer , vol.90 , pp. 20-25
    • Wong, Z.W.1    Ellis, M.J.2
  • 6
    • 0035687926 scopus 로고    scopus 로고
    • A longitudinal study of health related quality of life and utility measures in patients with advanced breast cancer
    • D.J. Perez S.M. Williams E.A. Christensen R.O. McGee A.V. Campbell A longitudinal study of health related quality of life and utility measures in patients with advanced breast cancer Qual Life Res 10 2001 587-593
    • (2001) Qual. Life Res. , vol.10 , pp. 587-593
    • Perez, D.J.1    Williams, S.M.2    Christensen, E.A.3    McGee, R.O.4    Campbell, A.V.5
  • 8
    • 7044238403 scopus 로고    scopus 로고
    • Same gain, less pain: Potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer
    • L. Fallowfield R. McGurk M. Dixon Same gain, less pain: Potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer Eur J Cancer 40 2004 2403-2410
    • (2004) Eur. J. Cancer , vol.40 , pp. 2403-2410
    • Fallowfield, L.1    McGurk, R.2    Dixon, M.3
  • 9
    • 0037453905 scopus 로고    scopus 로고
    • Health-related quality of life measurement in randomized clinical trials in breast cancer - Taking stock
    • P.J. Goodwin J.T. Black L.J. Bordeleau P.A. Ganz Health-related quality of life measurement in randomized clinical trials in breast cancer - taking stock J Natl Cancer Inst 95 2003 263-281
    • (2003) J. Natl. Cancer Inst. , vol.95 , pp. 263-281
    • Goodwin, P.J.1    Black, J.T.2    Bordeleau, L.J.3    Ganz, P.A.4
  • 10
    • 0029803177 scopus 로고    scopus 로고
    • Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer
    • A. Messori P. Becagli S. Trippoli E. Tendi Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer Eur J Clin Pharmacol 51 1996 111-116
    • (1996) Eur. J. Clin. Pharmacol. , vol.51 , pp. 111-116
    • Messori, A.1    Becagli, P.2    Trippoli, S.3    Tendi, E.4
  • 11
    • 0034002168 scopus 로고    scopus 로고
    • Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer - Is it cost effective?
    • J. Norum Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer - is it cost effective? Acta Oncol 39 2000 33-39
    • (2000) Acta Oncol. , vol.39 , pp. 33-39
    • Norum, J.1
  • 12
    • 0027474520 scopus 로고
    • Should the elderly receive chemotherapy for node-negative breast cancer? Cost-effectiveness analysis examining total and active life-expectancy outcomes
    • C.E. Desch B.E. Hillner T.E. Smith S.M. Retchin Should the elderly receive chemotherapy for node-negative breast cancer? Cost-effectiveness analysis examining total and active life-expectancy outcomes J Clin Oncol 11 1993 777-782
    • (1993) J. Clin. Oncol. , vol.11 , pp. 777-782
    • Desch, C.E.1    Hillner, B.E.2    Smith, T.E.3    Retchin, S.M.4
  • 13
    • 0026020636 scopus 로고
    • Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model
    • B.E. Hillner T.E. Smith Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model N Engl J Med 17 1991 160-168
    • (1991) N. Engl. J. Med. , vol.17 , pp. 160-168
    • Hillner, B.E.1    Smith, T.E.2
  • 14
    • 10644285714 scopus 로고    scopus 로고
    • Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective
    • A. Naeim E.B. Keeler Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective Crit Rev Oncol Hematol 53 2005 81-89
    • (2005) Crit. Rev. Oncol. Hematol. , vol.53 , pp. 81-89
    • Naeim, A.1    Keeler, E.B.2
  • 15
    • 0036211226 scopus 로고    scopus 로고
    • Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: A stochastic economic evaluation
    • Adjuvant Breast Cancer (ABC) Steering Committee
    • J. Karnon J. Brown Adjuvant Breast Cancer (ABC) Steering Committee. Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: A stochastic economic evaluation Pharmacoeconomics 20 2002 119-137
    • (2002) Pharmacoeconomics , vol.20 , pp. 119-137
    • Karnon, J.1    Brown, J.2
  • 16
    • 0027400930 scopus 로고
    • The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women
    • T.J. Smith B.E. Hillner The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women J Clin Oncol 11 1993 771-776
    • (1993) J. Clin. Oncol. , vol.11 , pp. 771-776
    • Smith, T.J.1    Hillner, B.E.2
  • 17
    • 4444291699 scopus 로고    scopus 로고
    • Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early stage estrogen receptor-positive breast cancer
    • B.E. Hillner Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early stage estrogen receptor-positive breast cancer Cancer 101 2004 1311-1322
    • (2004) Cancer , vol.101 , pp. 1311-1322
    • Hillner, B.E.1
  • 18
    • 0003193675 scopus 로고
    • Systemic therapy of early breast cancer by hormonal, cytotoxic ore immune therapy
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Systemic therapy of early breast cancer by hormonal, cytotoxic ore immune therapy Lancet 339 1992 1-15
    • (1992) Lancet , vol.339 , pp. 1-15
  • 21
    • 11444251764 scopus 로고    scopus 로고
    • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    • ATAC Trialists' Group
    • ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60-62
    • (2005) Lancet , vol.365 , pp. 60-62


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.